Cancer du rein : actualités 2008

25 septembre 2008

Auteurs : J.-J. Patard, E. Lechevallier, A. Descazeaud
Référence : Prog Urol, 2008, 18, S135, suppl. S6
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

Ljungberg B., Hanbury D.C., Kuczyk M.A., Merseburger A.S., Mulders P.F.A., Patard J.J., et al. Renal cell carcinoma guideline Eur Urol 2007 ;  51 : 1502-1510 [cross-ref]
 
Trabulsi E.J., Kalra P., Gomella L.G. New approaches to the minimally invasive treatment of kidney tumors Cancer J 2005 ;  11 : 57-63 [cross-ref]
 
American Cancer Society. Available at URL: www.cancer.org/. Accessed September 2007.
 
Schmidbauer J., Remzi M., Memarsadeghi M., Klinger H.C., Wiener H., Hainz-Peer G., et al. Diagnostic accuracy of percutaneous biopsy of renal masses guided by computerized tomography Eur Urol Suppl 2007 ;  6 : 132(abstract no. 440).  [cross-ref]
 
Mattar K., Azuero J., Rendon R., Morash C., Siemens D.R., Chin J.L., et al. The natural history of small renal masses: a prospective multi-center Canadian trial J Urol 2007 ;  177 (Suppl) : 169-170(abstract no. 509).
 
Nguyen M.M., Stein R.J., Hafron J.M., Aron M., Columbo J.R., Gianduzzo T.R., et al. The metastatic potential of small renal cancers is higher than previously believed J Urol 2007 ;  177 (Suppl) : 167(abstract no. 501).
 
Crispen P.L., Dougherty J., Greenberg R.E., Chen D., Uzzo R.G. High nuclear grade is associated with increased growth kinetics during active surveillance of clear cell renal carcinoma J Urol 2007 ;  177 (Suppl) : 215-216(abstract no. 642).
 
Trinh Q.D., Karakiewicz P., Jeldres C., Salomon L., De La Taille A., Tostain J, et al. Age is a major determinant of renal cell carcinoma-specific mortality after nephrectomy Eur Urol Suppl 2007 ;  6 : 63(abstract no. 163).  [cross-ref]
 
Crepel M., Verhoest G., Bernhard J.C., Ferrière J.M., Bellec L., Soulié M., et al. Impact of histology on cancer control after nephron sparing surgery for renal cell carcinoma Eur Urol Suppl 2007 ;  6 : 133(abstract no. 443).  [cross-ref]
 
Zini L., Leroy X., Garnier-Destrieux L., Fantoni J.C., Lemaitre L., Biserte J., et al. Inferior vena cava (IVC) wall invasion by a tumour thrombus in renal cell carcinoma: prediction of invasion and correlation with disease progression J Urol 2007 ;  177 (Suppl) : 300(abstract no. 904).
 
Klatte T., Wunderlich H., Patard J.-J., Kleid M.D., Lam J.S., Junker K., et al. Prognosis and survival of synchronous bilateral renal cell carcinoma: a multicenter experience J Urol 2007 ;  177 (Suppl) : 303-304(abstract no. 915).
 
Lane B.R., Babineau D., Gill I.S., Novick A.C. Factors predicting renal functional outcome after partial nephrectomy J Urol 2007 ;  177 (Suppl) : 211-212(abstract no. 631).
 
Gill I.S., Kavoussi L.R., Lane B.R., Blute M.L., Babineau D., Colombo J.R., et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors J Urol 2007 ;  178 : 41-46 [cross-ref]
 
Lane B.R., Gill I.S. Five year outcomes of laparoscopic partial nephrectomy J Urol 2007 ;  177 (Suppl) : 165-166(abstract no. 496).
 
Lane B.R., Novick A.C. Comparison of laparoscopic and open partial nephrectomy for a single renal tumour in a solitary kidney J Urol 2007 ;  177 (Suppl) : 217-218(abstract no. 648).
 
Beri A., Lattouf J.B., Gruüll M., Leeb K., Jeschke S., Janetschek G. Laparoscopic partial nephrectomy using renal artery perfusion for cold ischemia J Urol 2007 ;  177 (Suppl) : 407-408(abstract no. 1237).
 
Pertia A., Managadze L. Long-term results of simple enucleation for the treatment of small renal carcinoma Eur Urol Suppl 2007 ;  6 : 65(abstract no. 170).  [cross-ref]
 
Johnson A., Bratslavsky G., Sudarshan S., Liu J., Linehan W.M., Pinto P.A. Feasibility and outcomes of repeat partial nephrectomy on the same kidney: NCI experience J Urol 2007 ;  177 (Suppl) : 427(abstract no. 1298).
 
Schwentner C., Lunacek A., Pelzer A.E., Steiner H., Neururer R., Bartsch G., et al. Single center experience and extended follow-up of robotic partial nephrectomy J Urol 2007 ;  177 (Suppl) : 409(abstract no. 1241).
 
Vander Eeckt K., Joniau S., Van Poppel H. Outcome of nephron sparing surgery for T1b renal cell carcinoma Eur Urol Suppl 2007 ;  6 : 265(abstract no. 972).  [cross-ref]
 
Trinh Q.-D., Karakiewicz P.I., Bhojani N., Fournier-Cloutier V., Hutterer G.C., Crepel M., et al. Nephronsparing surgery does not undermine renal cell carcinoma- specific survival in patients with pT3 renal cell carcinoma J Urol 2007 ;  177 (Suppl) : 411(abstract no. 1246).
 
Huang W.C., Elkin E.B., Jang T.L., Russo P. Radical nephrectomy is associated with increased mortality in patients with small renal tumors J Urol 2007 ;  177 (Suppl) : 164-165(abstract no. 493).  [inter-ref]
 
Thompson R.H., Boorjian S.A., Lohse C.M., Leibovich B.C., Blute M.L. Is partial nephrectomy for small renal masses associated with improved overall survival compared with radical nephrectomy? J Urol 2007 ;  177 (Suppl) : 215(abstract no. 641).
 
Nomiya T., Tsuji H., Hirasawa N., Kato H., Kamada T., Mizoe J., et al. Carbon Ion Radiotherapy for Renal Cell Carcinoma: Outcome of a Pilot Study Int J Radiat Oncol Biol Phys 2007 ;  69 : S324(Abstract no 2219).
 
Thomas A., Lane B.R., Rini B.I., Campbell S.C. Effect of sunitinib in patients with unresectable primary renal cell carcinoma J Urol 2007 ;  177 (Suppl) : 167-168(abstract no. 502).
 
Bukowski R.M., Eisen T., Szczylik C., Stadler W.M., Simantov R., Shan M., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma; survival and biomarker analysis J Clin Oncol 2007 ;  25 (Suppl) : 240s(abstract no. 5023).
 
Motzer R.J., Figlin R.A., Hutson T.E., Tomczak P., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa (IFN-⍺) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors J Clin Oncol 2007 ;  25 (Suppl) : 241s(abstract no. 5024).
 
Golshayan A., Choueiri T.K., Elson P., Garcia J.A., Khaswneh M., Usman S., et al. Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy J Clin Oncol 2007 ;  25 (Suppl) : 246s(abstract no. 5046).
 
Choueiri T.K., Vaziri S.A., Rini B.I., Elson P., Bhalla I., Jaeger E., et al. Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) - targeted therapy in metastatic renal cell carcinoma (RCC) J Clin Oncol 2007 ;  25 (Suppl) : 238s(abstract no. 5012).
 
Szczylik C., Demkow T., Staehler M., Rolland F., Negrier S., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma:Final results J Clin Oncol 2007 ;  25 (Suppl) : 241s(abstract no. 5025).
 
Patard J.-J., Rioux-Leclercq N., Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma Eur Urol. 2006 ;  49 : 633-643 [cross-ref]
 
Escudier B., Koralewski P., Pluzanska A., Ravaud A., Bracarda S., Szcylik C., et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-⍺2a vs. placebo/interferon-⍺2a as first-line therapy in metastatic renal cell carcinoma J Clin Oncol 2007 ;  25 (Suppl) : 2s(abstract no. 3).
 
Plantade A., Choueiri T., Escudier B., Rini B., Negrier S., Ravaud A., et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib J Clin Oncol 2007 ;  25 (Suppl) : 244s(abstract no. 5037).
 
Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Phaze III randomized trial of sunitnib malate (SU1 1248) versus interferon- alfa (IFN-⍺) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) J Clin Oncol 2006 ;  24 (Suppl) : 2(abstract no. LBA3).
 
Dutcher J.P., Szczylik C., Tannir N., Benedetto P., Ruff P., Hsu A., et al. Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) J Clin Oncol 2007 ;  25 (Suppl) : 243s(abstract no. 5033).
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.